Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00043537 · ClinicalTrials.gov registry record · Phase 3
Treatment of Childhood Social Phobia
A Phase 3 study of Social Phobia, sponsored by University of Central Florida.
- Completed
- Registry status
- Phase 3
- Development phase
- 139
- Enrollment target
- 1
- Study location
NCT00043537 is a Phase 3 study of Social Phobia that has completed, run by University of Central Florida. The registered enrollment target is 139 participants, roughly in line with the 133-participant average among 8 other Social Phobia trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT00043537, a Phase 3 study of Social Phobia, has completed, sponsored by University of Central Florida.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 139 participants
- Enrollment target
- 1
- Study location
Study Summary
This 4-year study will compare the long-term effectiveness of behavioral treatment, fluoxetine (Prozac®), and placebo for treatment of social phobia in children and adolescents.
Conditions Studied
Interventions
- DRUG Fluoxetine
- DRUG Pill Placebo
- BEHAVIORAL Social Effectiveness Therapy for Children (SET-C)
Study Locations (1)
Maryland
- Maryland Center for Anxiety Disorders - University of Maryland, College Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2001-04 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00043537
The ClinicalTrials.gov registry entry for NCT00043537 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 133-participant average among 8 other Social Phobia trials with a reported enrollment target. The listed sponsor is University of Central Florida, which has 91 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Social Phobia appearing as the primary indexed condition, and to 3 interventions - of which Fluoxetine is the first listed.
NCT00043537 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00043537 about?
NCT00043537 is a clinical study titled "Treatment of Childhood Social Phobia". This 4-year study will compare the long-term effectiveness of behavioral treatment, fluoxetine (Prozac®), and placebo for treatment of social phobia in children and adolescents.
What is the current status of trial NCT00043537?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 139 participants. The study started on 2001-04. Estimated completion is 2006-09.
What conditions does trial NCT00043537 study?
This clinical trial studies the following conditions: Social Phobia.
What interventions are being tested in trial NCT00043537?
The interventions under investigation include: Fluoxetine (DRUG), Pill Placebo (DRUG), Social Effectiveness Therapy for Children (SET-C) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00043537?
This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00043537 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Phobia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mindful Self-Compassion for Anxiety Disorders and Depression
RECRUITING · NA
-
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
ACTIVE NOT RECRUITING · NA
-
Psychotherapy for Anxiety in Children With Autism Spectrum Disorder
COMPLETED · NA
-
Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder
COMPLETED · Phase 2
-
Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder
COMPLETED · Phase 2
-
Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.